AdAlta is extending Phase I clinical studies for its lead i-body® enabled candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of its i-body® platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development.
- Forums
- ASX - By Stock
- 1AD
- Ann: AdAlta presenting at ASX Gems conference
Ann: AdAlta presenting at ASX Gems conference, page-4
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
|
|||||
Last
2.1¢ |
Change
-0.001(4.55%) |
Mkt cap ! $12.50M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.1¢ | $10.70K | 509.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 1131730 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.3¢ | 1679 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 1131730 | 0.021 |
5 | 1376841 | 0.020 |
3 | 1108500 | 0.019 |
2 | 305553 | 0.018 |
1 | 1000000 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.023 | 1679 | 1 |
0.024 | 82500 | 1 |
0.025 | 290056 | 3 |
0.026 | 100000 | 1 |
0.027 | 162643 | 3 |
Last trade - 15.52pm 16/08/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |